Open AccessCombination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells
Author(s) -
Mei Zhu,
Hongmei Wang,
Shujuan Zhou,
Jia Wei,
Naiqing Ding,
Jie Shao,
Lan Yu,
Zhenqing Feng,
Baorui Liu
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s291086
Subject(s) - in vivo , cancer research , immune system , tumor microenvironment , t cell , immunotherapy , in vitro , cytotoxic t cell , cd3 , antibody , chemistry , antigen , cd8 , medicine , immunology , biology , biochemistry , microbiology and biotechnology
T cell-redirecting bispecific antibodies (BsAbs) are emerging as a potent cancer therapy that crosslinks tumor cells and T cells by simultaneously binding to tumor-associated antigen and CD3ε. However, immune inhibitory molecules can be remarkably upregulated after BsAbs treatment, leading to a suppressive tumor microenvironment and treatment resistance. This can be partially reversed by combination with immune checkpoint inhibitors. In our previous work, we successfully constructed the recombinant protein iRGD-antiCD3 and demonstrated that it promoted antitumor efficacy of transferred T cells by promoting T cell activation and infiltration.